An investigation for investors in NASDAQ:ANTH shares was announced concerning possible violations of securities laws by Anthera Pharmaceuticals and certain of its directors and officers..
Investors who purchased shares of Anthera Pharmaceuticals Inc (NASDAQ:ANTH), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.
The investigation by a law firm focuses on whether certain statements by Anthera Pharmaceuticals regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
On November 10, 2016, Anthera Pharmaceuticals Inc announced that “the CHABLIS-SC1 clinical trial with blisibimod for the treatment of systemic lupus erythematosus (SLE) failed to meet its primary endpoint based upon the SLE Responder Index-6 (SRI-6) at 52 weeks.”
On December 27, 2016, Anthera Pharmaceuticals Inc announced that its SOLUTION Phase 3 Study for liprotamase also failed to meet its primary endpoint. The Company announced it would conduct a new study of liprotamase. Shares of Anthera Pharmaceuticals Inc (NASDAQ:ANTH) declined to as low as $0.64 per share on December 30, 2016.
On January 20, 2017, NASDAQ:ANTH shares closed at $0.602 per share.
Those who purchased NASDAQ:ANTH shares have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North – Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com